Pharma company’s R1.8bn ARV tender windfall
01 March 2019 | Web Article Number: ME201913707
PHARMACEUTICAL heavyweight Adcock Ingram has been awarded a 12% share of the government’s National Anti-Retroviral (ARV) Tender, a windfall totalling approximately R1.8 billion (excluding VAT) over the next three years.
Ashley Pearce, Managing Director of the company’s Prescription Division said it had submitted bids for the triple combination products, Tenofovir/Emtricitabine/Efavirenz (TEE) and Dolutegravir/Lamivudine/Tenofovir (DLT), as well as a number of the dual and monotherapy molecules.
Adcock Ingram’s share of the ARV Tender award over the three years starting 1 July 2019 includes 11% (16.8 million packs) of the 147 million packs of DLT requested in the tender, 2.8 million packs of other oral solid dosage products and 2.7 million bottles of oral solutions.
Pearce said the company’s investment into the oral solid dosage facility in Wadeville had increased its ability to manufacture and supply antiretroviral medicines to the public sector through the tender system, and also meet the needs of the private healthcare market.
“Adcock Ingram is proud to have been chosen as one of the State’s partners in the fight against one of the biggest epidemics in the world,” he said.
“As a responsible South African manufacturer and supplier of ARV’s, our business model is focused firmly within our ethos of Adding Value to Life and in line with our quest to advance affordable healthcare for all South Africans. We look forward to continuing this partnership with government – united in the fight against AIDS.”
He added that as a member of Proudly South Africa, the company had its roots firmly entrenched in the South African market. “We are proud to be a leading South African manufacturer, which has been recognised as a partner of the State in the national fight against HIV and AIDS. The tender award reflects positively on our manufacturing capability, breadth of our product offering and our historical service delivery levels.”